Close Menu

NEW YORK – In a document filed with the US Securities and Exchange Commission on Wednesday, Progenity said that it is trimming its workforce by around 10 percent and revealed that a commercial insurer is seeking recoupment of $27.4 million from the firm in alleged overpayments.

The company it is terminating approximately 67 employees, who will exit before the end of this year. The termination benefits will cost the company $1.3 million, it noted.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.